Array ( [slave_lp] => Array ( [hostname] => 129.80.64.116 [username] => lpe [password] => jhvnaRSw98*#Je [database] => local_pages [dbdriver] => mysqli [dbprefix] => [pconnect] => [db_debug] => [cache_on] => [cachedir] => [char_set] => utf8 [dbcollat] => utf8_general_ci [swap_pre] => [autoinit] => 1 [stricton] => ) ) Array ( [slave_lp] => Array ( [hostname] => 129.80.64.116 [username] => lpe [password] => jhvnaRSw98*#Je [database] => local_pages [dbdriver] => mysqli [dbprefix] => [pconnect] => [db_debug] => [cache_on] => [cachedir] => [char_set] => utf8 [dbcollat] => utf8_general_ci [swap_pre] => [autoinit] => 1 [stricton] => ) ) Array ( [slave_lp] => Array ( [hostname] => 129.80.64.116 [username] => lpe [password] => jhvnaRSw98*#Je [database] => local_pages [dbdriver] => mysqli [dbprefix] => [pconnect] => [db_debug] => [cache_on] => [cachedir] => [char_set] => utf8 [dbcollat] => utf8_general_ci [swap_pre] => [autoinit] => 1 [stricton] => ) ) Array ( [slave_lp] => Array ( [hostname] => 129.80.64.116 [username] => lpe [password] => jhvnaRSw98*#Je [database] => local_pages [dbdriver] => mysqli [dbprefix] => [pconnect] => [db_debug] => [cache_on] => [cachedir] => [char_set] => utf8 [dbcollat] => utf8_general_ci [swap_pre] => [autoinit] => 1 [stricton] => ) )

Aytu biopharma announces strategic shift to focus on commercial operations and indefinite suspension of clinical development programs

Following a corporate review, aytu biopharma is indefinitely suspending clinical development and removing expenses related to ar101/enzastaurin, healight, and nt0502, and focusing on revenue growth and near-term cash flow generation aytu is expecting to generate positive quarterly adjusted ebitda in the first half of calendar 2023 expected future clinical development savings of more than $20m englewood, co / accesswire / october 13, 2022 / aytu biopharma, inc. (the company or "aytu") (nasdaq:aytu), a pharmaceutical company focused on commercializing novel therapeutics, today announced a shift of the company's strategy aimed at accelerating the growth of its commercial business and achieving profitability. as a result, the company is announcing the indefinite suspension of its clinical development programs, including ar101/enzastaurin for the treatment of vascular ehlers-danlos syndrome (veds).
AYTU Ratings Summary
AYTU Quant Ranking